On May 16, 2017, the FDA concluded that the Type 2 diabetes medication Canagliflozin (Invokana, Invokamet and Invokamet XR) causes an increased risk of leg and foot amputations. The FDA will now require the most prominent black box warning to be added to the Canagliflozin drug labels. This new warning came at the conclusion of two large clinical trials, one of which showed that leg and foot amputations occurred about twice as often in patients treated with Canagliflozin versus a placebo.
The Unsafe Drug and Medical Device Team at Anapol Weiss is investigating Canagliflozin cases on behalf of patients who have suffered an amputation. In the event you receive any calls regarding these products, we welcome the opportunity to work with you and your clients.